1 / 12

Discussion 22 Inhibitors and Drugs

Discussion 22 Inhibitors and Drugs. Questions. Explain how an inhibitor of glutamine:fructose aminotransferase (GFAT) would affect glycosylation? From a mechanistic point of view, how can an alkaloid that inhibits a glycosidase also block a glycosyltransferase?

mercer
Download Presentation

Discussion 22 Inhibitors and Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Discussion 22Inhibitors and Drugs

  2. Questions • Explain how an inhibitor of glutamine:fructose aminotransferase (GFAT) would affect glycosylation? • From a mechanistic point of view, how can an alkaloid that inhibits a glycosidase also block a glycosyltransferase? • Propose chemical modifications to make to galactose to create an inhibitor of sialyltransferases. • How would you go about obtaining an inhibitor of glycans that are initiated by the addition of O-fucose to EGF repeats in Notch? • Design a glycan-based therapeutic that acts by blocking the interaction of a naturally occurring glycan with glycan-binding proteins on an intact (or live) microbe.  • Identify at least two enzymes that might be targets for designing inhibitors of selectin-mediated cell adhesion and propose a strategy for obtaining selective inhibitors. • How can an enzyme inhibitor also act as a chemical chaperone? • The binding affinity of hemagglutinin to monomeric sialic acid is very weak, with a Kd in the millimolar range. Explain how influenza virus manages to bind to host cells with very high avidity despite the weak affinity of its receptor for sialic acid.   • A portion of erythropoietin (EPO) produced by CHO cells is not full sialylated (i.e., some glycoforms have exposed galactose residues on their N-glycans). What sugars might be added to the cell culture media to increase the overall level of EPO sialylation? • Explain how increasing the extent of glycosylation of recombinant glycoproteins can increase their half-life in vivo. • Describe the potential deleterious effects of producing recombinant therapeutic proteins in cultured animal cells of non-human origin.

  3. Fig. 50.1

  4. Fig. 50.2

  5. 50.3 GlcNAcstatin PUGNAc NAG-thiazoline

  6. Fig. 50.4

  7. Fig. 50.5

  8. Fig. 50.6

  9. Fig. 50.7

  10. Figure 51.1. Examples of natural products possessing glycan components. Streptomycinand erythromycin are antibiotics, doxorubicin is an anti-cancer drug and digoxin is usedto treat cardiovascular disease.

  11. Figure 51.2. The synthetic influenza neuraminidase inhibitors RelenzaTM and TamifluTM.

  12. Figure 51.3. Glycomimetic E-selectin inhibitors based on sialyl Lewis X.

More Related